Summary
Mexiletine in doses of 50, 100 and 400 mg was administered by intramuscular injection to a healthy subject and the resulting plasma concentrations were compared with those after 100 mg given intravenously. The bioavailability of mexiletine given by this route is complete and the kinetics are linear with dose. Plasma mexiletine concentrations resulting from 200 mg given orally with either two 4-ml intramuscular injections each containing 100 mg (Mexitil® — for intravenous use) or one 2-ml intramuscular injection of an experimental preparation containing 200 mg were compared in 3 and 6 normal subjects respectively. Plasma levels within the therapeutic range of 0.75–2 µg/ml were attained at mean times of 28.7 and 42.5 min respectively. Apart from raised plasma creatine phosphokinase levels (as would be expected following an intramuscular injection) the tolerability of intramuscular mexiletine injections was satisfactory. Further studies in patients will be required to determine whether the combined oral and intramuscular administration of mexiletine is of value in acute myocardial infarction.
Similar content being viewed by others
References
Campbell NPS, Chaturvedi NC, Kelly JG, Strong JE, Shanks RG, Pantridge JF (1973) Mexiletine (Kö 1173) in the management of ventricular arrhythmias. Lancet 2: 404–407
Campbell NPS, Kelly JG, Adgey AAJ, Shanks RG (1978a) Mexiletine in normal volunteers. Br J Clin Pharmacol 6: 372–373
Campbell NPS, Kelly JG, Adgey AAJ, Shanks RG (1978b) The clinical pharmacology of mexiletine. Br J Clin Pharmacol 6: 103–108
Fried J, Zietz S (1973) Curve fitting by Spline and Akima methods: possibility of interpolation error and its suppression. Phys Med Biol 18: 550–558
Gibaldi M, Perrier D (1975) Drugs and the pharmaceutical sciences. In: Swarbrick J (ed) Pharmacokinetics, vol 1, 1st edn. Marcel Dekker, New York, pp 33–40
Jebson P (1971) Intramuscular lignocaine 2% and 10%. Br Med J 3: 566–567
Kelly JG, Nimmo J, Rae R, Shanks RG, Prescott LF (1973) Spectrophotofluorometric and gas-liquid chromatographic methods for the estimation of mexiletine (Kö 1173) in plasma and urine. J Pharm Pharmacol 25: 550–553
Nelder JA, Mead R (1965) A simplex method for function minimisation. Computer J 7: 308–313
Pottage A (1977) Oral dosage schedules for mexiletine. Postgrad Med J 53 (Suppl 1): 155–157
Prescott LF, Pottage A, Clements JA (1977) Absorption, distribution and elimination of mexiletine. Postgrad Med J 53 (Suppl 1): 50–55
Schriftman H, Kondritzer AA (1957) Absorption of atropine from muscle. Am J Physiol 191: 591–594
Sidell FR (1974) Modification by diluents of effects of intramuscular atropine on heart rate in man. Clin Pharmacol Ther 16: 711–715
Talbot RG, Julian DG, Prescott LF (1976) Longterm treatment of ventricular arrhythmias with oral mexiletine. Am Heart J 91: 58–65
Wing LMH, Meffin PJ, Grygiel JJ, Smith KJ, Birkett DJ (1980) The effect of metoclopramide and atropine on the absorption of orally administered mexiletine. Br J Clin Pharmacol 9: 505–509
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bradbrook, I.D., Feldschreiber, P., Morrison, P.J. et al. Plasma mexiletine concentrations following combined oral and intramuscular administration. Eur J Clin Pharmacol 19, 301–304 (1981). https://doi.org/10.1007/BF00562808
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00562808